Jobs

Currently 3824 jobs

Candidates Login

CV Database

Let the jobs come to you!

Company Login

Site Newsletter

Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

PharmiWeb on Facebook

Advertising

Press Releases

submit a press release

146 Press Releases

1 2 3 4 5

Date	Title	Company
23 Jun 11	Data on MLN8237, an Investigational Aurora A Kinase Inhibitor, Presented at International Lymphoma Conference	Millennium: The Takeda Oncology Company, Published by Business Wire
11 Jun 11	Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Hodgkin Lymphoma at EHA Annual Meeting	Millennium: The Takeda Oncology Company, Published by Business Wire
10 Jun 11	Data Presentations Showcase Millennium Leadership in Protein Homeostasis at 16th Congress of the European Hematology Association	Millennium: The Takeda Oncology Company, Published by Business Wire
10 Jun 11	Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting	Millennium: The Takeda Oncology Company, Published by Business Wire
07 Jun 11	Novel VELCADE Based Combinations Show High Responses in Heavily Pre-Treated Patients with Relapsed or Refractory Multiple Myeloma	Millennium: The Takeda Oncology Company, Published by Business Wire
06 Jun 11	Millennium Highlights New Protein Homeostasis Data in Metastatic Melanoma and Other Solid Tumors at American Society of Clinical Oncology	Millennium: The Takeda Oncology Company, Published by Business Wire
06 May 11	VELCADE Improved Outcomes in Multiple Myeloma Patients After Transplant in Nordic Myeloma Study	Millennium: The Takeda Oncology Company, Published by Business Wire
05 May 11	Millennium Leadership in Proteasome Inhibition Highlighted in Relapsed/Refractory Multiple Myeloma At IMW Meeting	Millennium: The Takeda Oncology Company, Published by Business Wire
26 Apr 11	Millennium Submits Two Supplemental NDAs to FDA for VELCADE	Millennium: The Takeda Oncology Company, Published by Business Wire
15 Apr 11	Anti-Cancer Agent AMG 479 Enters into the Phase III Clinical Trial in Japan	Takeda, Published by PharmiWeb.com
11 Apr 11	HEPTARES AND TAKEDA INITIATE DRUG DISCOVERY COLLABORATION FOCUSED ON GPCR LINKED TO CNS DISORDERS	TAKEDA, Published by PharmiWeb.com
11 Apr 11	HEPTARES AND TAKEDA INITIATE DRUG DISCOVERY COLLABORATION FOCUSED ON GPCR LINKED TO CNS DISORDERS	Heptares Therapeutics and Takeda Pharmaceutical , Published by PharmiWeb.com
04 Feb 11	Journal of Clinical Oncology Publishes Clinical Trial Results of VELCADE Combination in Aggressive Subtypes of Non-Hodgkin Lymphoma	Millennium: The Takeda Oncology Company, Published by Business Wire
20 Jan 11	Fortune Magazine Names Millennium Among 100 Best Companies to Work For	Millennium: The Takeda Oncology Company, Published by Business Wire
09 Dec 10	VELCADE Induction Followed by VELCADE Maintenance Improves Clinical Outcomes in Previously Untreated Multiple Myeloma Patients	Millennium: The Takeda Oncology Company, Published by Business Wire
08 Dec 10	Weekly VELCADE in Combination with Rituximab Improves Progression-Free Survival and Response Rate in Patients with Relapsed or Refractory Follicular Lymphoma	Millennium: The Takeda Oncology Company, Published by Business Wire
07 Dec 10	Oral Presentation Showcases Results of MLN4924 in Patients with Acute Myeloid Leukemia or High-Grade Myelodysplastic Syndromes	Millennium: The Takeda Oncology Company, Published by Business Wire
02 Dec 10	Baxter and Takeda Complete Agreement for Vero Cell-Based Influenza Vaccines in Japan	Baxter International Inc. and Takeda Pharmaceutical Company Limited, Published by Business Wire
10 Nov 10	VELCADE® (bortezomib) Induction, Maintenance and Subcutaneous Data in Multiple Myeloma to Be Featured in Oral Presentations At American Society of Hematology Annual Meeting	Millennium: The Takeda Oncology Company, Published by Business Wire
04 Nov 10	Millennium and Takeda Announce Advancement of Prostate Cancer Program	Millennium: The Takeda Oncology Company, Published by Business Wire
20 Oct 10	Takeda Submits European Marketing Authorisation Application for Azilsartan Medoxomil, an Investigational Compound for the Treatment of Essential Hypertension	Takeda Pharmaceutical , Published by PharmiWeb.com
08 Oct 10	Science Magazine Ranks Millennium Among Top Biopharma Companies in the World	Millennium: The Takeda Oncology Company, Published by Business Wire
22 Sep 10	Recommendations for angiotensin receptor blockers updated in new NICE guidance on chronic heart failure	Takeda UK, Published by PharmiWeb.com
15 Sep 10	Millennium Sales Force Ranked #1 by Independent Survey of Leading Oncologists	Millennium: The Takeda Oncology Company, Published by Business Wire
27 Aug 10	Recommendations for angiotensin receptor blockers updated in new NICE guidance on chronic heart failure	Takeda UK
29 Jul 10	Study Analysis Identifies Potential Biomarkers of VELCADE (Bortezomib) Activity in Patients with Relapsed Mantle Cell Lymphoma	Millennium: The Takeda Oncology Company, Published by Business Wire
08 Jun 10	New Clinical Data on Millennium Solid Tumor Compounds Presented at American Society of Clinical Oncology	Millennium: The Takeda Oncology Company, Published by Business Wire
05 Jun 10	VELCADE® (bortezomib) Data in Relapsed or Refractory Amyloidosis Presented at American Society of Clinical Oncology Annual Meeting	Millennium: The Takeda Oncology Company, Published by Business Wire
10 May 10	Takeda to Co-Promote VELCADE® (bortezomib) for Injection in Japan	Millennium: The Takeda Oncology Company, Published by Business Wire
29 Apr 10	Journal of Clinical Oncology Publishes Data on Overall Survival Benefit of VELCADE® (Bortezomib) for Injection in Patients with Previously Untreated Multiple Myeloma	Millennium: The Takeda Oncology Company, Published by Business Wire

1 2 3 4 5

subscribe in a reader

Advertising

Share | | |

Site Map
Privacy & Security
Cookies
Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.